Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…Bar graphs depicted EVO increased mRNA expression of (D) SM22α and decreased (E) RUNX2 in CER treated P_i-induced VSMCs. …”

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. by Yue Chen (73753)

Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.... by Indrani Bera (804948)

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 49.6, <i>p</i> = 2.6 × 10⁻¹², condition: intensity interaction F = 1.94, <i>p</i> = 0.02, nested ANOVA (mouse nested within session), F = 56.5, <i>p</i> = 8.8 × 10⁻¹⁴, condition: intensity interaction F = 3.5, <i>p</i> = 3.5 × 10⁻⁰⁵). …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Dataset: Response diversity increases functional but decreases compositional stability of grassland communities by Robert Junker (19802088)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Relationship between monthly NDVI and climatic variables values (Tmax, maximum air temperature; P, precipitation; VPD, vapor pressure deficit), in areas with decreasing trends (<i>p</i> < 0.05). by Oswaldo Maillard (20660661)

Decreased cytokine expression in J2.2-HKU1.7b-infected BMDM. by Chaminda D. Gunawardene (22794593)

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)